News: Genome Maintenance Research Program

Understanding how a steroid-metabolizing enzyme binds to its substrates may aid in designing drugs to treat sexual dysfunction as well as prostate cancer.

A recent study suggests that blocking the MYC protein could be “unexpectedly effective” in treating malignant rhabdoid tumor (MRT) is one of the most aggressive and lethal childhood cancers.

A precise understanding of how the enzyme topoisomerase II cuts DNA could lead to better anti-cancer therapies.

A recent study found that renal cell carcinoma cells with mutations in an enzyme-encoding gene, SETD2, were sensitive to a drug that inhibits the enzyme PI3K-beta.

Vanderbilt investigators have discovered a new DNA repair pathway that guards against genomic mutations. Their findings were published recently in the journal Cell.

Changes in enzymes involved in lysophospholipid signaling can activate a pathway implicated in development of cancer, a recent study suggests.

Vanderbilt researchers have linked a specific form of programmed cell death to myelodysplastic syndrome, a type of bone marrow failure.

Vanderbilt scientists have identified 593 proteins that are enriched at sites of DNA duplication and chromatin packaging of newly synthesized DNA.

A recent study shows that a component of the DNA primase enzyme acts as a reversible on/off switch for DNA binding and represents a fundamentally new method of communication between DNA-processing enzymes.

Vanderbilt chemists have been awarded $7.2 million over the next five years from the National Cancer Institute to lead an initiative to better understand how a combination chemotherapy for breast cancer targets DNA.